L-Kynurenine
|
Basic information |
| Metabolite name | L-Kynurenine |
 | HMDB0000684 |
 |
C00328 |
 |
161166 |
| Synonyms | Kynurenine |
| No. of studies | 77 |
|
Basic information |
| Metabolite name | L-Kynurenine |
| HMDB0000684 |
|
C00328 |
|
161166 |
| Synonyms | Kynurenine |
| No. of studies | 77 |
|
Relationship between L-Kynurenine and depression (count: 77) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M046 | Type1 | LPS group vs. control group | Central amygdala | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Nucleus accumbens | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Ventral hippocampus | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Dorsal hippocampus | C57BL/6N mouse | Up |
| Study M046 | Type1 | LPS group vs. control group | Brain | C57BL/6N mouse | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Down |
| Study M1004 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1004 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Up |
| Study M1004 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M1014 | Type1 | lipopolysaccharide group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1014 | Type1 | lipopolysaccharide group vs. control group | Brain | C57BL/6J mouse | Down |
| Study M1014 | Type2 | lipopolysaccharide + 1-(1H-Imidazole-5-yl)-9H-pyrido[3,4-b]indole group vs. lipopolysaccharide group | Brain | C57BL/6J mouse | Up |
| Study M1014 | Type2 | lipopolysaccharide + 1-(1H-Imidazole-5-yl)-9H-pyrido[3,4-b]indole group vs. lipopolysaccharide group | Serum | C57BL/6J mouse | Up |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M1015 | Type1 | lipopolysaccharide group vs. control group | Cortex | C57BL/6J mouse | Up |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + high dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + amitriptyline group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + low dose of soy isoflavones group vs. lipopolysaccharide group | Hippocampus | C57BL/6J mouse | Down |
| Study M1015 | Type2 | lipopolysaccharide + middle dose of soy isoflavones group vs. lipopolysaccharide group | Cortex | C57BL/6J mouse | Down |
| Study M1025 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic diarrhea group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic constipation group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1034 | Type1 | small intestinal bacterial overgrowth and chronic diarrhea group vs. control group | Urine | Human | Up |
| Study M1034 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Up |
| Study M1035 | Type2 | mood disorder group, after tryptophan-rich diet vs. baseline | Urine | Human | Down |
| Study M1036 | Type1 | IBS-D group vs. control group | Urine | Human | Up |
| Study M1040 | Type2 | CUMS + Roseburia inulinivorans group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1051 | Type1 | tumor-bearing group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M1051 | Type2 | tumor-bearing + epacadostat group vs. tumor-bearing group | Serum | C57BL/6J mouse | Down |
| Study M1059 | Type1 | CRS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M1059 | Type1 | CRS group vs. control group | Serum | Wistar rat | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1081 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1081 | Type2 | CUMS + 1-methyl-tryptophan group vs. CUMS group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Brain | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1081 | Type3 | 1-methyl-tryptophan group vs. control group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type1 | interferon gamma group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1082 | Type1 | interferon gamma group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Serum | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Colon | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + 1-methyl-tryptophan group vs. interferon gamma group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Brain | C57BL/6 J mouse | Down |
| Study M1082 | Type2 | interferon gamma + Pulsatilla chinensis saponins group vs. interferon gamma group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1083 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1083 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1083 | Type2 | CUMS + Pulsatilla chinensis saponins group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M1084 | Type1 | CUMS group vs. control group | Colon | C57BL/6 J mouse | Up |
| Study M1084 | Type1 | CUMS group vs. control group | Brain | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Colon | C57BL/6 J mouse | Down |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Serum | C57BL/6 J mouse | Up |
| Study M1084 | Type2 | CUMS + Mesalazine group vs. CUMS group | Brain | C57BL/6 J mouse | Down |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Colon | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1108 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1139 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M115 | Type2 | MDD treated group 8-week vs. baseline | Plasma | Human | Up |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M142 | Type1 | SNI group vs. control group | Plasma | C57/BL6J mouse | Up |
| Study M147 | Type3 | SD acute vortioxetine group vs. SD acute control group | Brain | Sprague-Dawley rat | Up |
| Study M171 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M171 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M171 | Type2 | CUMS + DXS group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M172 | Type1 | postpartum depression group vs. postpartum group | Serum | Human | Down |
| Study M175 | Type2 | ECT treatment depressed group post-treatment vs. baseline | Plasma | Human | Down |
| Study M178 | Type1 | depressed group vs. control group | Serum | Human | Down |
| Study M450 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M459 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M489 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M524 | Type1 | hydrocortisone group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M524 | Type2 | hydrocortisone + Tiansi Liquid group vs. hydrocortisone group | Plasma | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M550 | Type2 | CUMS + GTD group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M570 | Type1 | CMS group vs. control group | Cerebral cortex | BALB/c mouse | Up |
| Study M570 | Type1 | CMS group vs. control group | Serum | BALB/c mouse | Up |
| Study M570 | Type1 | CMS group vs. control group | Hippocampus | BALB/c mouse | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M596 | Type1 | elderly depression group vs. elderly control group | Urine | Human | Up |
| Study M602 | Type4 | responder group vs. non-responder group | Plasma | Human | Down |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Serum | C57BL/6 J mouse | Down |
| Study M627 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M627 | Type1 | CUMS group vs. control group | Colon | Sprague-Dawley rat | Up |
| Study M627 | Type1 | CUMS group vs. control group | Cortex | Sprague-Dawley rat | Up |
| Study M684 | Type1 | LPS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M684 | Type2 | LPS + electroacupuncture group vs. LPS group | Hippocampus | Wistar rat | Down |
| Study M701 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M724 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M728 | Type1 | CRS group vs. control group | Ileum | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M728 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M728 | Type2 | CRS + citalopram group vs. CRS group | Colon | C57BL/6 J mouse | Down |
| Study M729 | Type2 | CRS + 1-methyl-tryptophan group vs. CRS group | Hippocampus | C57BL/6 J mouse | Down |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M748 | Type1 | short-day group vs. long-day group | Plasma | C57BL/6 J mouse | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M777 | Type1 | HFCS-MFD group vs. control group | Serum | C57Bl/6J mouse | Down |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M779 | Type2 | depression group, post vs. before treatment | Plasma | Human | Up |
| Study M783 | Type1 | stroke + CUMS group vs. stroke group | Faece | Sprague-Dawley rat | Up |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Up |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Up |
| Study M879 | Type1 | unipolar depression group vs. control group | Plasma | Human | Down |
| Study M884 | Type1 | CSDS group vs. control group | Urine | C57BL/6J mouse | Up |
| Study M884 | Type1 | CSDS group vs. control group | Ileum | C57BL/6J mouse | Up |
| Study M884 | Type1 | CSDS group vs. control group | Faece | C57BL/6J mouse | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M906 | Type2 | after rTMS treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M913 | Type4 | responder group vs. nonresponder group, at baseline | Plasma | Human | Down |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M972 | Type1 | CRS + irradiation group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M972 | Type2 | CRS + irradiation + Paeoniae Radix Alba group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + albiflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M976 | Type1 | small intestinal bacterial overgrowth group vs. control group | Urine | Human | Up |
| Study M976 | Type2 | small intestinal bacterial overgrowth group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Down |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Up |
| Study M983 | Type1 | adolescent MDD group vs. adolescent control group | Plasma | Human | Up |